Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/103714
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wu, T. | - |
dc.contributor.author | Xie, C. | - |
dc.contributor.author | Wu, H. | - |
dc.contributor.author | Jones, K. | - |
dc.contributor.author | Horowitz, M. | - |
dc.contributor.author | Rayner, C. | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, 2017; 19(2):290-293 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.issn | 1463-1326 | - |
dc.identifier.uri | http://hdl.handle.net/2440/103714 | - |
dc.description.abstract | In rodents, metformin slows intestinal glucose absorption, potentially increasing exposure of the distal gut to glucose to enhance postprandial glucagon-like peptide-1 (GLP-1) secretion. We evaluated the effects of metformin on serum 3-O-methylglucose (3-OMG; a marker of glucose absorption) and plasma total GLP-1 concentrations during a standardized intraduodenal infusion of glucose and 3-OMG in patients with type 2 diabetes. A total of 12 patients, treated with metformin 850 mg twice daily or placebo for 7 days each in a double-blind, randomized, crossover design (14 days’ washout between treatments), were evaluated on days 5 or 8 of each treatment (6 subjects each). On each study day, 30 minutes after ingesting 850 mg metformin or placebo, patients received an infusion of glucose (60 g + 5 g 3-OMG, dissolved in water to 240 mL) via an intraduodenal catheter over the course of 120 minutes. Compared with placebo, metformin was associated with lower serum 3-OMG (P < .001) and higher plasma total GLP-1 (P = .003) concentrations. The increment in plasma GLP-1 after metformin vs placebo was related to the reduction in serum 3-OMG concentrations (P = .019). Accordingly, metformin inhibits small intestinal glucose absorption, which may contribute to augmented GLP-1 secretion in type 2 diabetes. | - |
dc.description.statementofresponsibility | Tongzhi Wu MD, Cong Xie, Hang, Karen L. Jones, Michael Horowitz, Christopher K. Rayner | - |
dc.language.iso | en | - |
dc.publisher | Wiley | - |
dc.rights | © 2016 John Wiley & Sons Ltd | - |
dc.source.uri | http://dx.doi.org/10.1111/dom.12812 | - |
dc.subject | 3-O-methylglucose; glucagon-like pepetide-1; intestinal glucose absorption; metformin | - |
dc.title | Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/dom.12812 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/627011 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Wu, T. [0000-0003-1656-9210] | - |
dc.identifier.orcid | Xie, C. [0000-0002-0054-9269] | - |
dc.identifier.orcid | Jones, K. [0000-0002-1155-5816] | - |
dc.identifier.orcid | Horowitz, M. [0000-0002-0942-0306] | - |
dc.identifier.orcid | Rayner, C. [0000-0002-5527-256X] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.